Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

• Sarolta Bojtine Kovacs,
• Jingting Luan,
• Sandra Maria Dold,
• Andreas Weis,
• Milena Pantic,
• Justus Duyster,
• Ralph Wäsch,
• Monika Engelhardt

Affiliations

Sarolta Bojtine Kovacs

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg

Jingting Luan

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg

Sandra Maria Dold

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Faculty of Biology, University of Freiburg

Andreas Weis

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Milena Pantic

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg

Justus Duyster

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Ralph Wäsch

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Monika Engelhardt

Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany